ADVERTISEMENT
  • News
  • New York
  • Technology
  • Culture
  • Entertainment
  • Sport
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Monday, April 7, 2025
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Business Pharmacy

Novartis study shows Onbrez Breezhaler is superior to salmeterol in reducing breathlessness

The FINANCIAL by The FINANCIAL
September 20, 2010
in Pharmacy
Reading Time: 3 mins read
8
A A
0
Share on FacebookShare on Twitter

The FINANCIAL — Results of the Phase III INSIST study show that Onbrez Breezhaler (indacaterol) given once-daily is significantly better at improving lung function and reducing breathlessness than twice-daily salmeterol[1], one of the current mainstays of treatment for patients with chronic obstructive pulmonary disease (COPD).

Patients with COPD using the novel Onbrez Breezhaler were also able to reduce their use of rescue medication compared to those using salmeterol[1], a widely prescribed drug in the long-acting beta-2 agonist (LABA) class. Onbrez Breezhaler has been described in scientific literature as the first "ultra-LABA" reflecting its longer duration of action compared to older LABAs[2].

Data from the INSIST study involving 1,123 patients aged 40 years or above in seven countries were presented today at the European Respiratory Society (ERS) congress in Barcelona, Spain. Results showed that Onbrez Breezhaler 150 µg once-daily provided superior 24-hour bronchodilation to salmeterol 50 µg twice-daily at the end of 12 weeks' treatment[1].

RelatedPosts

A Closer Look at Bioactive Peptides and Their Impact on Health

Roche ranked the most sustainable healthcare company in the DJSI

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

"Patients with COPD require treatment that combines a sustained improvement in lung function with better clinical outcomes," said the study's principal investigator, Dr Stephanie Korn from the Pulmonary Department at Mainz University Hospital in Germany. "The results of INSIST confirm that indacaterol is potentially an attractive maintenance treatment option for these patients."

COPD is a progressive, life-threatening disease associated with tobacco smoking, air pollution or occupational exposure, which causes obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. Although often considered a disease of the elderly, research has shown that a majority of COPD patients are under the age of 65[3], when they are likely to be at the peak of their earning power and family responsibilities.

INSIST was a 12-week, randomized, double-blind, head-to-head study involving patients with moderate-to-severe COPD (as defined by the GOLD 2007 criteria[4]). The study met its primary endpoint with Onbrez Breezhaler giving superior bronchodilation to salmeterol at week 12[1]. This was assessed by measuring patients' forced expiratory volume of breath in one second (FEV1) from five minutes to 11 hours 45 minutes post-dose (mean difference in FEV1 area under curve 60 mL, p<0.001)[1]. Onbrez Breezhaler showed superiority for this assessment in all subgroups of patients[1].

In addition, Onbrez Breezhaler significantly increased the proportion of patients with a clinically relevant reduction in breathlessness compared to salmeterol (69.4% vs. 62.7% achieved a score of at least one in the transition dyspnea index, p<0.05), and the number of days on which patients did not require rescue medication (mean difference 4.4%, p<0.05)[1]. Both treatments were well tolerated in the study[1].

"By demonstrating the benefits that Onbrez Breezhaler can bring to patients with COPD, this study affirms our confidence in this medicine and in the indacaterol-based combination therapies currently under development," said Trevor Mundel, MD, Global Head of Development at Novartis AG. "Novartis is committed to providing innovative treatment options for patients with COPD and their physicians as part of our long-standing involvement in the field of respiratory medicine."

The INSIST study findings are supported by recently published data from the 26-week INLIGHT-2 Phase III study involving 1,002 patients with moderate-to-severe COPD[5]. In this study, Onbrez Breezhaler 150 µg once-daily provided a greater improvement in lung function after 12 weeks than salmeterol 50 µg twice-daily or placebo (24-hour trough FEV1 increased by 60 mL more than salmeterol and 170 mL more than placebo, both p<0.001)[5]. Safety profiles were similar across the treatment groups and both active treatments were well tolerated[5].

Onbrez Breezhaler is approved in more than 40 countries including the European Union, Switzerland, Australia, India, Indonesia, Korea, and a number of countries in Latin America. It is indicated in Europe for the maintenance bronchodilator treatment of airflow obstruction in adult patients with COPD[6]. US approval is subject to the FDA's review of additional clinical data that Novartis expects to file by the end of 2010.

In clinical studies, the most commonly reported adverse reactions with Onbrez Breezhaler were nasopharyngitis, upper respiratory tract infection, cough and headache[6].

COPD affects 210 million people worldwide[7] and is projected to be the third leading cause of death by 2020[8]. The symptoms cause profound disability and COPD is a major burden on individual patients, their families, and society at large. Early diagnosis and effective treatment are a key priority, because although COPD is incurable, the disease is manageable with appropriate therapies.

 

 

Related Posts

A Closer Look at Bioactive Peptides and Their Impact on Health
Clinics

A Closer Look at Bioactive Peptides and Their Impact on Health

by Accessily
October 15, 2024
0

Introduction to Bioactive Peptides What are Bioactive Peptides? Bioactive peptides are short protein fragments, typically ranging from 2 to 20...

Read more
Roche ranked the most sustainable healthcare company in the DJSI

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020
Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

November 16, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

November 12, 2020

Discussion about this post

  • Trending
  • Comments
  • Latest
Bvlgari, Ferrari & Louis Vuitton: 3 Exceptional New Partners for the International Master in Luxury Management

Bvlgari, Ferrari & Louis Vuitton: 3 Exceptional New Partners for the International Master in Luxury Management

March 31, 2025
Eshvi Signals The Beginning of a Bold New Era by Opening A New Location

Eshvi Signals The Beginning of a Bold New Era by Opening A New Location

April 1, 2025
Ampersand wins £22m five-year contract at London Zoo

Ampersand wins £22m five-year contract at London Zoo

June 25, 2012
Fort Lauderdale’s Coolest Spots: A Guide to the City’s Must-Visit Destinations

Fort Lauderdale’s Coolest Spots: A Guide to the City’s Must-Visit Destinations

March 30, 2025
New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

April 3, 2025
European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

April 6, 2025
Loans

Protected: What Are the Factors That Affect Housing Loan Interest Rates?

April 5, 2025
How Do Bullet-Resistant Windows Improve Safety?

How Do Bullet-Resistant Windows Improve Safety?

April 3, 2025
New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

April 3, 2025
How to Deep Clean Your Air Fryer in 5 Easy Steps

How to Deep Clean Your Air Fryer in 5 Easy Steps

April 3, 2025
ADVERTISEMENT

Popular Last 24h

  • Eshvi Signals The Beginning of a Bold New Era by Opening A New Location

    Eshvi Signals The Beginning of a Bold New Era by Opening A New Location

    108 shares
    Share 43 Tweet 27
  • European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

    20 shares
    Share 8 Tweet 5
  • Ampersand wins £22m five-year contract at London Zoo

    3007 shares
    Share 1203 Tweet 752
  • What Are the Income Limits for Deducting Traditional IRA Contributions in 2025?

    40 shares
    Share 16 Tweet 10
  • Boost Your Online Presence:

    29 shares
    Share 12 Tweet 7
  • New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

    41 shares
    Share 16 Tweet 10
  • How Do Bullet-Resistant Windows Improve Safety?

    22 shares
    Share 9 Tweet 6

LATEST POSTS

European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

April 6, 2025
Loans

Protected: What Are the Factors That Affect Housing Loan Interest Rates?

April 5, 2025
How Do Bullet-Resistant Windows Improve Safety?

How Do Bullet-Resistant Windows Improve Safety?

April 3, 2025
New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

April 3, 2025
How to Deep Clean Your Air Fryer in 5 Easy Steps

How to Deep Clean Your Air Fryer in 5 Easy Steps

April 3, 2025
Muslim Pro App CEO Addresses Data Privacy Concerns and Outlines Enhanced Security Measures

Muslim Pro App CEO Addresses Data Privacy Concerns and Outlines Enhanced Security Measures

April 3, 2025
Between 1979 and 2022, the total register has increased by 4.1 million companies

Tariff-ic government?

April 3, 2025
retirement-mza.jpg

What Are the Income Limits for Deducting Traditional IRA Contributions in 2025?

April 3, 2025
Energy bills are the area of spending most concerning Britons

Energy bills are the area of spending most concerning Britons

April 1, 2025
Homelessness Crisis in New York: The Intersection with Illegal Immigration

Homelessness Crisis in New York: The Intersection with Illegal Immigration

April 1, 2025

LATESTINTERVIEWS

Interview: Former British Air Commander Says Ukraine Must ‘Inflict Maximum Pain’ On Russia

Interview: Former British Air Commander Says Ukraine Must ‘Inflict Maximum Pain’ On Russia

by The FINANCIAL
September 17, 2024
0

Bizzy Cold Brew CEO Reveals What’s Fueling Ambitiously Strong Brand

Bizzy Cold Brew CEO Reveals What’s Fueling Ambitiously Strong Brand

by Merilee Kern, MBA

Washington Wants to Avoid a Repeat of Last Year’s NATO Summit

Washington Wants to Avoid a Repeat of Last Year’s NATO Summit

by The FINANCIAL
June 28, 2024
0

Tamar Ghlonti, the Acting Director of Radio Maestro

Radio Maestro: Promoting Business Growth and Development in Georgia

by Golden Brand
June 15, 2024
0

Lika Lobzhanidze, founder and director of ArtPharma

Vitaferol – Top Vitamin D brand in Georgia

by Golden Brand
June 15, 2024
0

Tea Meskhi, the Marketing Manager of the Turkish pharmaceutical company Asfarma

Customer Satisfaction, Trust Lead Aksen Fort to Win Golden Brand in Georgia

by Golden Brand
June 15, 2024
0

Aleksandre Metreveli - Director of the company

Ekokemika Service Group to Unveil New Line of Household Chemicals This Year

by Golden Brand
June 15, 2024
0

Lasha Babuadze, The-founder of Iberia Product

Anchor Butter Georgian Customers’ Favorite for The Fifth Time at Golden Brand Awards

by Golden Brand
June 15, 2024
0

GET IN TOUCH

Submit guest post/Letters to the Editor:

editor (at) finchannel.com

Sales & Marketing: (+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com

Whatsup: +995599965252

USA:

+1 917-795-8866

Georgia:

(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2025 Intelligence Group llc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

- Select Visibility -

    This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.